ArticleAmerican journal of cancer research2025
Predictive value of baseline CT imaging features combined with serum biomarkers for neoadjuvant chemotherapy response in adenocarcinoma of the gastroesophageal junction.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastroesophageal junction (GEJ) adenocarcinoma, located at the esophagus-stomach junction, poses significant clinical challenges due to its complex physiological structure. Neoadjuvant chemotherapy (NAC) is standard for tumor downstaging, but response variability necessitates reliable predictive markers. This study evaluates baseline computed tomography (CT) imaging parameters and serum markers as predictors for chemotherapy response in GEJ adenocarcinoma.
methodsA retrospective study included 304 GEJ adenocarcinoma patients treated with the SOX regimen (S-1 + Oxaliplatin) between January 2020 and December 2024. Patients were categorized based on Tumor Regression Grade (TRG) into effective (TRG 0-1) and poor response (TRG 2-3) groups. Baseline CT characteristics were assessed alongside serum markers, including carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9), and carbohydrate antigen 72-4 (CA 72-4). Multivariate logistic regression identified independent predictors, and a combined predictive model was developed and validated using an external cohort.
resultsThe effective treatment group showed significantly lower serum markers (CEA, AFP, CA 19-9, CA 72-4) and distinct CT parameters, including decreased maximum tumor thickness and area, and lower CT enhancement values. Extramural vascular invasion (EMVI) and tumor surface ulceration were associated with poor response. The combined predictive model demonstrated high accuracy, with an area under the curve (AUC) of 0.813 in the training set and 0.846 in the validation cohort.
conclusionBaseline CT characteristics, when combined with serum markers, effectively predict NAC response in GEJ adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.